Increased yield of endothelial cells from peripheral blood for cell therapies and tissue engineering.

TitleIncreased yield of endothelial cells from peripheral blood for cell therapies and tissue engineering.
Publication TypeJournal Article
Year of Publication2015
AuthorsJamiolkowski, RM, Kang, SD, Rodriguez, AK, Haseltine, JM, Galinat, LJ, Jantzen, AE, Carlon, TA, Darrabie, MD, Arciniegas, AJ, Mantilla, JG, Haley, NR, Noviani, M, Allen, JD, Stabler, TV, Frederiksen, JW, Alzate, O, Keil, LG, Liu, S, Lin, F-H, Truskey, GA, and Achneck, HE
JournalRegenerative medicine
Volume10
Issue4
Start Page447
Pagination447 - 460
Date Published05/2015
Abstract

Peripheral blood-derived endothelial cells (pBD-ECs) are an attractive tool for cell therapies and tissue engineering, but have been limited by their low isolation yield. We increase pBD-EC yield via administration of the chemokine receptor type 4 antagonist AMD3100, as well as via a diluted whole blood incubation (DWBI).Porcine pBD-ECs were isolated using AMD3100 and DWBI and tested for EC markers, acetylated LDL uptake, growth kinetics, metabolic activity, flow-mediated nitric oxide production and seeded onto titanium tubes implanted into vessels of pigs.DWBI increased the yield of porcine pBD-ECs 6.6-fold, and AMD3100 increased the yield 4.5-fold. AMD3100-mobilized ECs were phenotypically indistinguishable from nonmobilized ECs. In porcine implants, the cells expressed endothelial nitric oxide synthase, reduced thrombin-antithrombin complex systemically and prevented thrombosis.Administration of AMD3100 and the DWBI method both increase pBD-EC yield.

DOI10.2217/rme.15.2
Short TitleRegenerative medicine